MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2020

    Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study

    K.R Chaudhuri, J. Boyd, E. Cubo, I. Malaty, F. Pontieri, M. Simu, L. Bergmann, T. Gao, Y. Jalundhwala, P. Kukreja, J. Aldred (London, United Kingdom)

    Objective: To evaluate the relationship between sleep disturbances and quality of life (QoL) in advanced Parkinson’s disease (PD) patients both prior to and at month…
  • MDS Virtual Congress 2020

    Indication and long-term outcome of device-aided therapies in advanced Parkinson’s disease

    M. Shiraishi, F. Maki, M. Kato, Y. Morosawa, I. Takumi, K. Isahaya, N. Sasaki, Y. Hasegawa (Kawasaki, Japan)

    Objective: We aimed to demonstrate the real world differences in a single center. Background: Number of deep brain stimulation (DBS) and levodopa-carbidopa continuous infusion gel…
  • MDS Virtual Congress 2020

    Orthostatic hypotension in early onset Parkinson’s disease

    Z. Liu, D.N Su, J.H Zhou, T. Feng (Beijing, China)

    Objective: To investigate Orthostatic hypotension (OH)  feature in early onset Parkinson's disease (EOPD)  , especially delayed OH and acute OH post drug.  To explore OH…
  • MDS Virtual Congress 2020

    Motor subtype change between OFF and ON periods in patients with Parkinson’s disease

    O. Esquivel-Zapata, A. Abundes-Corona, F. Herrera-Rodriguez, O. Cardenas-Saenz, E. Escobar-Valdivia, Y. Ríos-Solís, H. Tellez-Lucero, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico, Mexico)

    Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…
  • MDS Virtual Congress 2020

    12-month therapeutic evaluation of l-dopa carbidopa ascorbic acid solution (LCAS) in a cohort of Advanced Parkinson’s disease in a North-Indian tertiary care hospital

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To prescribe LCAS to Parkinson’s disease(PD) patients whose symptoms were not adequately controlled on tablet l-dopa and compare the UPDRS-(I,II,III,IV) ON & OFF on…
  • MDS Virtual Congress 2020

    Sensorimotor inhibition relates to gait dysfunction in people with Parkinson’s disease

    D. Martini, G. Harker, R. Morris, J. Nutt, F. Horak (Portland, OR, USA)

    Objective: To determine how sensorimotor inhibition relates to objective measures of gait OFF and ON levodopa and how having Parkinson’s disease (PD) affects this relationship.…
  • MDS Virtual Congress 2020

    Claims Data Analysis of Parkinson’s Disease Medication Utilization

    M. Frazer, C. Blauer-Peterson, R. Sasane, S. Arcona, Y. Fang, R. Halpern (Eden Prairie, MN, USA)

    Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…
  • MDS Virtual Congress 2020

    Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation

    M. Soileau, F. Pagan, A. Fasano, R. Rodriguez-Cruz, M. Oh, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, M. Siddiqui (Georgetown, TX, USA)

    Objective: To compare the real-world impact of initiating carbidopa/levodopa enteral suspension (CLES) or deep brain stimulation (DBS) on reducing pill burden (i.e. total number of…
  • MDS Virtual Congress 2020

    Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?

    A.S Nordvig, R.N Alcalay, J.M Berger, K. Marder, G. Karsenty, A. Wang (New York, NY, USA)

    Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…
  • MDS Virtual Congress 2020

    Impact of dopamine 2/3 receptor agonists on the phenomenology of L-DOPA-induced dyskinesia in patients with Parkinson’s disease

    S. Grigoriou, S. Christiansson, P. Odin, M.A Cenci (Lund, Sweden)

    Objective: To investigate possible differences in phenomenology and temporal profile of dyskinesias in patients with Parkinson’s disease (PD) after challenge doses with levodopa alone or…
  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley